1. bookAHEAD OF PRINT
Journal Details
License
Format
Journal
eISSN
2501-062X
First Published
30 Mar 2015
Publication timeframe
4 times per year
Languages
English
access type Open Access

A Pilot Study of Changes in Urinary Podocalyxin Levels during Normal Pregnancy and Labor

Published Online: 06 May 2022
Volume & Issue: AHEAD OF PRINT
Page range: -
Received: 01 Mar 2022
Journal Details
License
Format
Journal
eISSN
2501-062X
First Published
30 Mar 2015
Publication timeframe
4 times per year
Languages
English
Abstract

Introduction. Increased urinary podocalyxin, a surrogate marker of podocyte detachment, has been shown in preeclampsia and eclampsia, but there is a paucity of data of the effect of normal pregnancy on its urinary excretion. We aimed to describe these changes in this pilot study.

Methods. Urine podocalyxin levels were measured in 115 pregnant women. Of these, 12 women were in the second trimester of gestation, 57 in the third trimester and 46 women were in labor.

Results. The median [IQR] urinary podocalyxin levels were 0.81 [0.27, 3.68], 0.92 [0.44, 5.49] and 64.7 [30.5, 106.3] ng/mg creatinine in the second trimester, third trimester, and during labor, respectively (p<0.0001). Patients with hematuria during labor had higher levels of urinary podocalyxin (128.6 [79.8, 169.6] ng/mg creatinine. There was a moderate correlation between gestational age and urinary podocalyxin levels (r=0.63, p<0.0001).

Conclusion. Urinary podocalyxin levels were low in normal pregnancies and increased significantly during labor and with hematuria.

Keywords

1. KUBIAK A, NIEMIR ZI. [The role of podocytes in normal glomerular function and in the pathogenesis of glomerulonephritis. Part I. Phenotypic and functional characteristics of podocytes during their differentiation and maturity]. Postepy Hig Med Dosw (Online). 2006;60:248-58. Search in Google Scholar

2. SNYDER KA, HUGHES MR, HEDBERG B, BRANDON J, HERNAEZ DC, BERGQVIST P, et al. Podocalyxin enhances breast tumor growth and metastasis and is a target for monoclonal antibody therapy. Breast Cancer Res. 2015;17(1):46.10.1186/s13058-015-0562-7 Search in Google Scholar

3. KELLEY TW, HUNTSMAN D, MCNAGNY KM, ROSKELLEY CD, HSI ED. Podocalyxin: a marker of blasts in acute leukemia. Am J Clin Pathol. 2005;124(1):134-42.10.1309/7BHLAHHU0N4MHT7Q Search in Google Scholar

4. SCHOPPERLE WM, KERSHAW DB, DEWOLF WC. Human embryonal carcinoma tumor antigen, Gp200/GCTM-2, is podocalyxin. Biochem Biophys Res Commun. 2003;300(2):285-90.10.1016/S0006-291X(02)02844-9 Search in Google Scholar

5. HARA M, YAMAMOTO T, YANAGIHARA T, TAKADA T, ITOH M, ADACHI Y, et al. Urinary excretion of podocalyxin indicates glomerular epithelial cell injuries in glomerulonephritis. Nephron. 1995;69(4):397-403.10.1159/0001885097777103 Search in Google Scholar

6. NIELSEN JS, MCNAGNY KM. The role of podocalyxin in health and disease. J Am Soc Nephrol. 2009;20(8):1669-76.10.1681/ASN.200807078219578008 Search in Google Scholar

7. CHEN Q, WANG Y, LI Y, ZHAO M, NIE G. Serum podocalyxin is significantly increased in early-onset preeclampsia and may represent a novel marker of maternal endothelial cell dysfunction. J Hypertens. 2017;35(11):2287-94.10.1097/HJH.000000000000146128665887 Search in Google Scholar

8. NAKAMURA T, USHIYAMA C, SUZUKI S, HARA M, SHIMADA N, EBIHARA I, et al. Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant. 2000;15(9):1379-83.10.1093/ndt/15.9.137910978394 Search in Google Scholar

9. PALACIOS DE FRANCO Y, VELAZQUEZ K, SEGOVIA N, ACOSTA C, YANOSKY D, FRANCO PALACIOS YV, et al. Urinary podocalyxin as a marker of preeclampsia in a Hispanic population. Int J Physiol Pathophysiol Pharmacol. 2014;6(2):115-24. Search in Google Scholar

10. CRAICI IM, WAGNER SJ, BAILEY KR, FITZ-GIBBON PD, WOOD-WENTZ CM, TURNER ST, et al. Podocyturia predates proteinuria and clinical features of preeclampsia: longitudinal prospective study. Hypertension. 2013;61(6):1289-96.10.1161/HYPERTENSIONAHA.113.01115371379323529165 Search in Google Scholar

11. ZHAI T, FURUTA I, AKAISHI R, ISHIKAWA S, MORIKAWA M, YAMADA T, et al. Alteration of podocyte phenotype in the urine of women with preeclampsia. Sci Rep. 2016;6:24258.10.1038/srep24258482365727052160 Search in Google Scholar

12. TANAMAI VW, SEAGLE BL, YEH JY, BRADY B, MILLER CB, SENA S, et al. Urine Protein/Creatinine Ratios during Labor: A Prospective Observational Study. PLoS One. 2016;11(8):e0160453.10.1371/journal.pone.0160453496882027479123 Search in Google Scholar

13. PALACIOS DE FRANCO Y, VELAZQUEZ K, SEGOVIA N, SANDOVAL G, GAUTO E, FRANCO PALACIOS YV, et al. Long term follow up of biomarkers of podocyte damage and renal function in patients with and without preeclampsia. J Bras Nefrol. 2018;40(4):339-43.10.1590/2175-8239-jbn-3941653400529782634 Search in Google Scholar

14. KOSTOVSKA I, TRAJKOVSKA KT, CEKOVSKA S, TOPUZOVSKA S, KAVRAKOVA JB, SPASOVSKI G, et al. Role of urinary podocalyxin in early diagnosis of diabetic nephropathy. Rom J Intern Med. 2020;58(4):233-41.10.2478/rjim-2020-002332780718 Search in Google Scholar

15. AIROLDI J, WEINSTEIN L. Clinical significance of proteinuria in pregnancy. Obstet Gynecol Surv. 2007;62(2):117-24.10.1097/01.ogx.0000253301.55009.ac17229328 Search in Google Scholar

16. TATENO H, MATSUSHIMA A, HIEMORI K, ONUMA Y, ITO Y, HASEHIRA K, et al. Podocalyxin is a glycoprotein ligand of the human pluripotent stem cell-specific probe rBC2LCN. Stem Cells Transl Med. 2013;2(4):265-73.10.5966/sctm.2012-0154365983123526252 Search in Google Scholar

17. ROBERTS M, LINDHEIMER MD, DAVISON JM. Altered glomerular permselectivity to neutral dextrans and heteroporous membrane modeling in human pregnancy. Am J Physiol. 1996;270(2 Pt 2):F338-43.10.1152/ajprenal.1996.270.2.F3388779896 Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo